

Evolut Clinical Guideline 3142 for Ayvakit™ (avapritinib)

Guideline Number: Evolut_CG_3142	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> <i>© 2020 - 2025 Evolut. All rights Reserved.</i>		
Original Date: February 2020	Last Revised Date: July 2025	Implementation Date: July 2025

TABLE OF CONTENTS

STATEMENT	2
PURPOSE	2
INDICATIONS	2
GASTROINTESTINAL STROMAL TUMOR (GIST)	2
SYSTEMIC MASTOCYTOSIS (SM)	2
CONTRAINDICATIONS/WARNINGS	2
EXCLUSION CRITERIA	3
CODING AND STANDARDS	3
CODES	3
APPLICABLE LINES OF BUSINESS	4
POLICY HISTORY	4
LEGAL AND COMPLIANCE	4
GUIDELINE APPROVAL	4
Committee	4
DISCLAIMER	4
REFERENCES	5

STATEMENT

Purpose

To define and describe the accepted indications for Ayvakit (avapritinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Gastrointestinal Stromal Tumor (GIST)

- The member has unresectable or metastatic GIST with a documented platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, and Ayvakit (avapritinib) may be used as monotherapy.

Systemic Mastocytosis (SM)

- Ayvakit (avapritinib) will be used as monotherapy in a member with indolent systemic mastocytosis (ISM), or aggressive/advanced systemic mastocytosis (AdvSM) [e.g., systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)], and the member's platelet count is greater than or equal to $50 \times 10^9/L$ prior to the start of therapy.

CONTRAINDICATIONS/WARNINGS

- None

EXCLUSION CRITERIA

- Ayvakit (avapritinib) is being used after disease progression with the same regimen.
- Use of Ayvakit (avapritinib) in PDGFRA wild type GIST.
- Concurrent use of another tyrosine kinase inhibitor (e.g., imatinib, sunitinib, regorafenib, sorafenib, dasatinib, or pazopanib).
- Dosing exceeds single dose limit of Ayvakit (avapritinib) 300 mg (for GIST), 200 mg (for Advanced SM), and 25 mg (for Indolent SM).
- Treatment exceeds the maximum limit of 30 (25 mg), 30 (50 mg), 30 (100 mg), 30 (200 mg), or 30 (300 mg) tablets/month.
- Investigational use of Ayvakit (avapritinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J8999 - avapritinib

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
July 2025	• Converted to new Evolent guideline template • This guideline replaces UM ONC_1378 Ayvakit (avapritinib) • Updated indication section • Updated maximum dosage form quantities in exclusion criteria • Updated exclusion criteria • Updated references
July 2024	• Updated NCH verbiage to Evolent

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is

a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Gotlib J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. *Nat Med*. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8.
2. DeAngelo DJ, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. *Nat Med*. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9.
3. Gotlib J, et al. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. *NEJM Evid*. 2023 Jun;2(6):EVIDo2200339. doi: 10.1056/EVIDo2200339.
4. Jones RL, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. *Eur J Cancer*. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008.
5. Blay JY, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2020 Jul;21(7):923-934. doi: 10.1016/S1470-2045(20)30168-6.
6. Ayvakit prescribing information. Blueprint Medicines Corporation, Cambridge, MA 2024.
7. Clinical Pharmacology Elsevier Gold Standard 2025.
8. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
9. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
10. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
11. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
12. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
13. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.